Page 226 - Williams Hematology ( PDFDrive )

200 Part IV: Molecular and Cellular Hematology Chapter 14: Metabolism of Hematologic Neoplastic Cells 201

and hematologic neoplasm alike for cell growth, proliferation, and sur- 27. Vousden KH, Ryan KM: p53 and metabolism. Nat Rev Cancer 9:691–700, 2009.
vival. Glucose and glutamine flux into cells provides for the production 28. Matoba S, Kang JG, Patino WD, et al: P53 regulates mitochondrial respiration. Science
312:1650–1653, 2006.
of ATP and building blocks for the growing cell. Furthermore, gluta- 29. Freed-Pastor WA, Mizuno H, Zhao X, et al: Mutant p53 disrupts mammary tissue
mine and glucose are also substrates for glutathione synthesis, which is architecture via the mevalonate pathway. Cell 148:244–258, 2012.
vital for redox homeostasis of growing cells that produce ROS as meta- 30. Xiong S, Tu H, Kollareddy M, et al: Pla2g16 phospholipase mediates gain-of-function
activities of mutant p53. Proc Natl Acad Sci U S A 111:11145–11150, 2014.
bolic byproducts. Resting cells, on the other hand, tend to rely on FAO, 31. Ortega-Molina A, Serrano M: PTEN in cancer, metabolism, and aging. Trends Endo-
which provides the most efficient energy production. In this regard, crinol Metab 24:184–189, 2013.
evidence has emerged indicating that neoplastic stem cells also rely on 32. Semenza GL: HIF-1 mediates metabolic responses to intratumoral hypoxia and onco-
FAO and, hence, could be targeted therapeutically via this route. Glu- genic mutations. J Clin Invest 123:3664–3671, 2013.
cose, glutamine, and mitochondrial metabolism pathways offer similar 33. Parks SK, Chiche J, Pouyssegur J: Disrupting proton dynamics and energy metabolism
for cancer therapy. Nat Rev Cancer 13:611–623, 2013.
inhibition strategies for proliferating hematologic neoplastic cells. One 34. Finkel T: Signal transduction by reactive oxygen species. J Cell Biol 194:7–15, 2011.
of the most remarkable therapeutic developments, however, is the dis- 35. Schieber M, Chandel NS: ROS function in redox signaling and oxidative stress. Curr
Biol 24:R453–R462, 2014.
covery of IDH mutations in AML and lymphoma and the development 36. Leinonen HM, Kansanen E, Polonen P, et al: Role of the Keap1-Nrf2 pathway in cancer.
of specific drugs targeting the mutant forms of IDH1 and IDH2. Fur- Adv Cancer Res 122:281–320, 2014.
thermore, alterations of the AML methylome and the ability of mutant 37. Dawson MA, Kouzarides T: Cancer epigenetics: From mechanism to therapy. Cell
150:12–27, 2012.
IDH inhibitors to induce differentiation of AML cells underscore the 38. Bhaumik SR, Smith E, Shilatifard A: Covalent modifications of histones during devel-
link between metabolites and the epigenome. It is through advances opment and disease pathogenesis. Nat Struct Mol Biol 14:1008–1016, 2007.
in our understanding of cancer metabolism that we have been able to 39. Kaelin WG Jr, McKnight SL: Influence of metabolism on epigenetics and disease. Cell
develop therapies like these for mutant IDH, capitalize on the avidity of 153:56–69, 2013.
glucose uptake by hematologic neoplasms for diagnostic and followup 40. Choudhary C, Weinert BT, Nishida Y, et al: The growing landscape of lysine acetylation
links metabolism and cell signalling. Nat Rev Mol Cell Biol 15:536–550, 2014.
FDG-PET scanning, and develop many more metabolic strategies that 41. Neff T, Armstrong SA: Recent progress toward epigenetic therapies: The example of
are hoped to provide new gains against these deadly malignancies. mixed lineage leukemia. Blood 121:4847–4853, 2013.
42. Shih AH, Abdel-Wahab O, Patel JP, Levine RL: The role of mutations in epigenetic reg-
ulators in myeloid malignancies. Nat Rev Cancer 12:599–612, 2012.
43. Simsek T, Kocabas F, Zheng J, et al: The distinct metabolic profile of hematopoietic stem
REFERENCES cells reflects their location in a hypoxic niche. Cell Stem Cell 7:380–390, 2010.
44. Takubo K, Goda N, Yamada W, et al: Regulation of the HIF-1alpha level is essential for
1. Schrodinger E: What is Life? Cambridge University Press, Cambridge, UK 1944. hematopoietic stem cells. Cell Stem Cell 7:391–402, 2010.
2. Bass J: Circadian topology of metabolism. Nature 491:348–356, 2012. 45. Gan B, Hu J, Jiang S, et al: Lkb1 regulates quiescence and metabolic homeostasis of
3. Berg J, Tymoczko JL, Stryer L: Biochemistry. WH Freeman, New York, 2002. haematopoietic stem cells. Nature 468:701–704, 2010.
4. Rabinowitz JD, White E: Autophagy and metabolism. Science 330:1344–1348, 2010. 46. Gurumurthy S, Xie SZ, Alagesan B, et al: The Lkb1 metabolic sensor maintains hae-
5. Orkin SH, Zon LI: Hematopoiesis: An evolving paradigm for stem cell biology. Cell matopoietic stem cell survival. Nature 468:659–663, 2010.
132:631–644, 2008. 47. Nakada D, Saunders TL, Morrison SJ: Lkb1 regulates cell cycle and energy metabolism
6. Dang CV: Links between metabolism and cancer. Genes Dev 26:877–890, 2012. in haematopoietic stem cells. Nature 468:653–658, 2010.
7. Rolfe DF, Brown GC: Cellular energy utilization and molecular origin of standard met- 48. Oburoglu L, Tardito S, Fritz V, et al: Glucose and glutamine metabolism regulate human
abolic rate in mammals. Physiol Rev 77:731–758, 1997. hematopoietic stem cell lineage specification. Cell Stem Cell 15:169–184, 2014.
8. Lippman SI, Broach JR: Protein kinase A and TORC1 activate genes for ribosomal bio- 49. Le A, Lane AN, Hamaker M, et al: Glucose-independent glutamine metabolism via
genesis by inactivating repressors encoded by Dot6 and its homolog Tod6. Proc Natl TCA cycling for proliferation and survival in B cells. Cell Metab 15:110–121, 2012.
Acad Sci U S A 106:19928–19933, 2009. 50. Fan J, Kamphorst JJ, Mathew R, et al: Glutamine-driven oxidative phosphorylation is a
9. Cantor JR, Sabatini DM: Cancer cell metabolism: One hallmark, many faces. Cancer major ATP source in transformed mammalian cells in both normoxia and hypoxia. Mol
Discov 2:881–898, 2012. Syst Biol 9:712, 2013.
10. Schell JC, Rutter J: The long and winding road to the mitochondrial pyruvate carrier. 51. Ito K, Carracedo A, Weiss D, et al: A PML-PPAR-delta pathway for fatty acid oxidation
Cancer Metab 1:6, 2013. regulates hematopoietic stem cell maintenance. Nat Med 18:1350–1358, 2012.
11. Chowdhury R, Sekirnik R, Brissett NC, et al: Ribosomal oxygenases are structurally 52. Farber S, Diamond LK: Temporary remissions in acute leukemia in children produced
conserved from prokaryotes to humans. Nature 510:422–426, 2014. by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med 238:787–793,
12. McDonough MA, Loenarz C, Chowdhury R, et al: Structural studies on human 2-oxog- 1948.
lutarate dependent oxygenases. Curr Opin Struct Biol 20:659–672, 2010. 53. Emadi A, Zokaee H, Sausville EA: Asparaginase in the treatment of non-ALL hemato-
13. Hensley CT, Wasti AT, DeBerardinis RJ: Glutamine and cancer: Cell biology, physiol- logic malignancies. Cancer Chemother Pharmacol 73:875–883, 2014.
ogy, and clinical opportunities. J Clin Invest 123:3678–3684, 2013. 54. Pui CH, Relling MV, Downing JR: Acute lymphoblastic leukemia. N Engl J Med 350:
14. DeBerardinis RJ, Cheng T: Q’s next: The diverse functions of glutamine in metabolism, 1535–1548, 2004.
cell biology and cancer. Oncogene 29:313–324, 2010. 55. Meyer SC, Levine RL: Translational implications of somatic genomics in acute myeloid
15. Fan J, Ye J, Kamphorst JJ, et al: Quantitative flux analysis reveals folate-dependent leukaemia. Lancet Oncol 15:e382–e394, 2014.
NADPH production. Nature 510:298–302, 2014. 56. Koppenol WH, Bounds PL, Dang CV: Otto Warburg’s contributions to current con-
16. Laplante M, Sabatini DM: Regulation of mTORC1 and its impact on gene expression at cepts of cancer metabolism. Nat Rev Cancer 11:325–337, 2011.
a glance. J Cell Sci 126:1713–1719, 2013. 57. Herst PM, Howman RA, Neeson PJ, et al: The level of glycolytic metabolism in acute
17. Roussel MF, Davis JN, Cleveland JL, et al: Dual control of myc expression through a sin- myeloid leukemia blasts at diagnosis is prognostic for clinical outcome. J Leukoc Biol
gle DNA binding site targeted by ets family proteins and E2F-1. Oncogene 9:405–415, 89:51–55, 2011.
1994. 58. Boag JM, Beesley AH, Firth MJ, et al: Altered glucose metabolism in childhood pre-B
18. Farrell AS, Sears RC: MYC degradation. Cold Spring Harb Perspect Med 4, 2014. acute lymphoblastic leukaemia. Leukemia 20:1731–1737, 2006.
19. Dang CV: MYC on the path to cancer. Cell 149:22–35, 2012. 59. Wernicke CM, Richter GH, Beinvogl BC, et al: MondoA is highly overexpressed in
20. Hardie DG: AMP-activated protein kinase: An energy sensor that regulates all aspects acute lymphoblastic leukemia cells and modulates their metabolism, differentiation
of cell function. Genes Dev 25:1895–1908, 2011. and survival. Leuk Res 36:1185–1192, 2012.
21. Mihaylova MM, Shaw RJ: The AMPK signalling pathway coordinates cell growth, 60. Kitoh T, Kubota M, Takimoto T, et al: Metabolic basis for differential glutamine require-
autophagy and metabolism. Nat Cell Biol 13:1016–1023, 2011. ments of human leukemia cell lines. J Cell Physiol 143:150–153, 1990.
22. Gallant P: Myc function in Drosophila. Cold Spring Harb Perspect Med 3:a014324, 2013. 61. Onuma T, Waligunda J, Holland JF: Amino acid requirements in vitro of human leuke-
23. Conacci-Sorrell M, McFerrin L, Eisenman RN: An overview of MYC and its interac- mic cells. Cancer Res 31:1640–1644, 1971.
tome. Cold Spring Harb Perspect Med 4:a014357, 2014. 62. Goto M, Miwa H, Shikami M, et al: Importance of glutamine metabolism in leukemia
24. Dang CV: Gene regulation: Fine-tuned amplification in cells. Nature 511:417–418, cells by energy production through TCA cycle and by redox homeostasis. Cancer Invest
2014. 32:241–247, 2014.
25. Golomb L, Volarevic S, Oren M. p53 and ribosome biogenesis stress: The essentials. 63. Willems L, Jacque N, Jacquel A, et al: Inhibiting glutamine uptake represents an
FEBS Lett 588:2571–2579, 2014. attractive new strategy for treating acute myeloid leukemia. Blood 122:3521–3532,
26. Mayer C, Grummt I: Ribosome biogenesis and cell growth: MTOR coordinates tran- 2013.
scription by all three classes of nuclear RNA polymerases. Oncogene 25:6384–6391, 64. Tiziani S, Kang Y, Harjanto R, et al: Metabolomics of the tumor microenvironment in
2006. pediatric acute lymphoblastic leukemia. PLoS One 8:e82859, 2013.

Kaushansky_chapter 14_p0191-0202.indd 201 17/09/15 6:36 pm